Search

Your search keyword '"Giannelli, V"' showing total 404 results

Search Constraints

Start Over You searched for: Author "Giannelli, V" Remove constraint Author: "Giannelli, V"
404 results on '"Giannelli, V"'

Search Results

1. The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients

2. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool

3. Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: Risk of HCC recurrence from a large, multicentre retrospective study from Italy

4. P295 WHEN TAVI IS THE RIGHT CHOICE

5. Nationwide survey of liver transplantation for Primary Sclerosing Cholangitis in Italy

6. Efficacy of lenvatinib in intermediate stage and advanced hepatocellular carcinoma: Results of monotherapy and combination with locoregional treatment

7. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

8. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

9. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation

12. SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study

14. The IMPROVEMENT project: first report of the global liver transplant activity

15. Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study

16. Different perceptions of sustainable case-mix for liver transplantation between surgeons and hepatologists: an Italian multicenter study

17. THE CASE-MIX IN LIVER TRANSPLANTATION. DIFFERENT PERCEPTIONS (TRANSPLANT SURGEONS AND TRANSPLANT HEPATOLOGISTS) AND DIFFERENT CONCORDANCE LEVELS WITHIN CENTERS

20. Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation

23. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

24. Sarco-model, a novel score to better predict the risk of death in cirrhotic patients awaiting liver transplantation

25. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

26. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

28. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

30. Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study

31. SANZIONI AMMINISTRATIVE, RES IUDICATA E INCOSTITUZIONALITÀ DELLA LEGGE APPLICATA DAL GIUDICE

32. ADVANCED CARDIAC IMAGING IN LIVER TRANSPLANTATION ECHOCARDIOGRAPHIC VENTRICULAR STRAIN AS PROGNOSTIC TOOLS

33. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

35. A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy

36. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients

37. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

38. Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience

41. The Persistence of HCV Replication Is Associated with an Increased Mortality Rate in HCV Recurrent Transplant Patients: Results from the AISF-RECOLT-C Group

46. FRI-379 - Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

47. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

Catalog

Books, media, physical & digital resources